RESUMEN
Some patients with ß thalassaemia experience non-progressive creatinine increases with deferasirox, mostly within normal limits; the mechanisms involved are not fully elucidated. The effects of deferasirox on renal haemodynamics, including glomerular filtration rate (GFR) and renal plasma flow (RPF), were investigated in a Phase I, open-label study in ß thalassaemia major patients with iron overload. Patients received deferasirox 30 mg/kg/d up to Week 8, followed by a 2-week washout period, and extended treatment up to Week 104 with a 4-week washout period. In the short-term study (n = 11), mean GFR and RPF declined from baseline to Week 8 (mean [%] change:-9·2 [-9·5%] and -105·7 ml/min [-17·8%], respectively). A similar pattern was observed during the long-term study (n = 5); mean GFR and RPF decreased up to Week 52 (-19·1 [-17·7%] and -155·6 ml/min [-26·1%]), with similar change at Week 104 (-18·4 [-17·2%] and -115·9 ml/min [-19·6%]). Measures returned to baseline values after each washout. Serum creatinine and creatinine clearance followed a similar pattern. Effects of deferasirox on renal haemodynamics were mild and reversible for up to 2 years of treatment, with no progressive worsening of renal function over time. www.clinicaltrials.gov: NCT00560820.
Asunto(s)
Benzoatos/farmacología , Quelantes del Hierro/farmacología , Circulación Renal/efectos de los fármacos , Reacción a la Transfusión , Triazoles/farmacología , Talasemia beta/fisiopatología , Adulto , Benzoatos/efectos adversos , Benzoatos/uso terapéutico , Biomarcadores/sangre , Biomarcadores/orina , Terapia por Quelación/efectos adversos , Terapia por Quelación/métodos , Creatinina/sangre , Deferasirox , Femenino , Ferritinas/sangre , Tasa de Filtración Glomerular/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Humanos , Quelantes del Hierro/efectos adversos , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Sobrecarga de Hierro/etiología , Masculino , Persona de Mediana Edad , Triazoles/efectos adversos , Triazoles/uso terapéutico , Adulto Joven , Talasemia beta/sangre , Talasemia beta/terapiaRESUMEN
The relationship between diabetes mellitus (DM) and cardiac complications has never been systematically studied in thalassaemia major (TM). We evaluated a large retrospective historical cohort of TM to determine whether DM is associated with a higher risk of heart complications. We compared 86 TM patients affected by DM with 709 TM patients without DM consecutively included in the Myocardial Iron Overload in Thalassaemia database where clinical/instrumental data are recorded from birth to the first cardiovascular magnetic resonance (CMR) exam. All of the cardiac events considered were developed after the DM diagnosis. In DM patients versus non-DM patients we found a significantly higher frequency of cardiac complications (46.5% vs. 16.9%, P < 0.0001), heart failure (HF) (30.2% vs. 11.7%, P < 0.0001), hyperkinetic arrhythmias (18.6% vs. 5.5%, P < 0.0001) and myocardial fibrosis assessed by late gadolinium enhancement (29.9% vs. 18.4%, P = 0.008). TM patients with DM had a significantly higher risk of cardiac complications [odds ratio (OR) 2.84, P < 0.0001], HF (OR 2.32, P = 0.003), hyperkinetic arrhythmias (OR 2.21, P = 0.023) and myocardial fibrosis (OR 1.91, P = 0.021), also adjusting for the absence of myocardial iron overload assessed by T2* CMR and for the covariates (age and/or endocrine co-morbidity). In conclusion, DM significantly increases the risk for cardiac complications, HF, hyperkinetic arrhythmias and myocardial fibrosis in TM patients.
Asunto(s)
Diabetes Mellitus/metabolismo , Cardiomiopatías Diabéticas/complicaciones , Cardiopatías/complicaciones , Sobrecarga de Hierro/complicaciones , Talasemia beta/complicaciones , Adulto , Estudios de Cohortes , Diabetes Mellitus/patología , Cardiomiopatías Diabéticas/metabolismo , Femenino , Cardiopatías/metabolismo , Cardiopatías/patología , Humanos , Sobrecarga de Hierro/metabolismo , Sobrecarga de Hierro/patología , Masculino , Estudios Retrospectivos , Talasemia beta/diagnóstico , Talasemia beta/metabolismo , Talasemia beta/patologíaRESUMEN
BACKGROUND: Transfusion-acquired hepatitis C virus (HCV) remains an important problem among patients with thalassemia. In this study, we evaluated the natural history of post-transfusional hepatitis C in thalassemia major, paying special attention to spontaneous viral clearance, to factors influencing the chronicity rate and fibrosis progression. DESIGN AND METHODS: A prospective study to evaluate the incidence and etiology of transfusion-related hepatitis was started in 1980. In patients who developed hepatitis C, HCV RNA, ALT, and ferritin were measured over time. The correlation between interleukin-28B gene polymorphisms and viral clearance was also analyzed. RESULTS: Seventy-three of 135 patients (62.2%) acquired HCV. An extended follow-up (22 to 30 yr) with HCV RNA assessment was available in 52 patients. Of them, 23 (44.2%) cleared the virus. The proportion of IL-28B genotypes was different between the subjects who cleared the virus and the subjects who did not. Fibrosis progression was similar in HCV RNA-positive and HCV RNA-negative patients. Liver iron was the only factor associated with the fibrosis. CONCLUSIONS: In thalassemia patients with HCV infection, liver iron does not play a major role in influencing the chronicity rate, whereas it is significantly associated with the fibrosis.
Asunto(s)
Transfusión Sanguínea , Patógenos Transmitidos por la Sangre , Hepacivirus , Hepatitis C Crónica , Interleucinas , Polimorfismo Genético , ARN Viral , Talasemia beta , Niño , Preescolar , Femenino , Estudios de Seguimiento , Hepacivirus/genética , Hepacivirus/metabolismo , Hepatitis C Crónica/sangre , Hepatitis C Crónica/genética , Humanos , Lactante , Interferones , Interleucinas/sangre , Interleucinas/genética , Hierro/metabolismo , Hígado/metabolismo , Hígado/virología , Masculino , Estudios Prospectivos , ARN Viral/sangre , ARN Viral/genética , Estudios Retrospectivos , Talasemia beta/sangre , Talasemia beta/genética , Talasemia beta/virologíaRESUMEN
We report a case of a 43-year-old woman, affected by human immunodeficiency virus (HIV) and beta-thalassemia major (beta-TM), adequately treated with antiretroviral and transfusion-chelation therapy, that develops progressive right ventricular dysfunction due to severe pulmonary arterial hypertension (PAH), in absence of symptoms. The existence of both HIV and beta-TM cardiomiopathy has recently been reported, but how these two diseases have a "competition of guilt" for creating PAH is still to be understood. The main physiopathological principles regarding HIV and beta-TM associated PAH are reviewed. The possible interplay between these two different pathologies is discussed.
Asunto(s)
Infecciones por VIH/complicaciones , Hipertensión Pulmonar/etiología , Talasemia beta/complicaciones , Adulto , Fármacos Anti-VIH/uso terapéutico , Transfusión Sanguínea , Quelantes/uso terapéutico , Femenino , Infecciones por VIH/epidemiología , Infecciones por VIH/fisiopatología , Humanos , Hipertensión Pulmonar/fisiopatología , Hipertensión Pulmonar/terapia , Talasemia beta/epidemiología , Talasemia beta/fisiopatologíaRESUMEN
BACKGROUND: Infection with hepatitis delta virus (HDV) affects approximately 6-14.5% of patients coinfected with HIV-1 and HBV, showing a more aggressive clinical course compared with an HIV-negative population. There is no universally approved treatment for chronic hepatitis D (CHD) in HIV-infected patients. Antiretroviral therapy (ART) containing tenofovir has been recently associated with HDV suppression. Our aim was to evaluate whether the outcome of CHD in HIV-infected patients can be favourably influenced by ART including reverse transcriptase inhibitors. METHODS: The clinical course of four HBV/HDV/HIV-coinfected patients receiving ART were retrospectively examined. RESULTS: HDV RNA became undetectable in all patients after a variable period of ART along with the disappearance of hepatitis B surface antigen in two of them, and an increase in CD4(+) T-cell count. In all patients, virological changes were associated with improved liver function tests and clinical features. CONCLUSIONS: We suggest that ART regimens including drugs active against HBV could have beneficial effects on the clinical course of CHD in patients with HIV-1 by favouring immunological reconstitution.
Asunto(s)
Terapia Antirretroviral Altamente Activa , Coinfección , Infecciones por VIH/tratamiento farmacológico , Hepatitis D/virología , Virus de la Hepatitis Delta , Biomarcadores , Recuento de Linfocito CD4 , Femenino , Infecciones por VIH/inmunología , Infecciones por VIH/virología , Hepatitis B/diagnóstico , Hepatitis B/virología , Hepatitis D/diagnóstico , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Carga ViralRESUMEN
Studies of the standardized, 3D, 16-segments map of the circumferential distribution of T2* values, of cardiovascular magnetic resonance (CMR) in thalassemia major (TM) and thalassemia intermedia (TI) patients and of electrocardiogram (ECG) changes associated with TM, have been carried out. Similarly, the segment-dependent correction map of the T2* values and the artifactual variations in normal subjects and the T2* correction map to correct segmental measurements in patients with different levels of myocardial iron burden have been evaluated. Cardiovascular magnetic resonance can be a suitable guide to cardiac management in TI, as well as in TM; TI patients show lower myocardial iron burden and more pronounced high cardiac output findings than TM patients. Moreover, it is proposed that, due to its good positive predictive value (PPV) and low cost, ECG can be a suitable guide to orient towards CMR examination in TM cases.